Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Head-to-Head, Single-Blinded Study to Assess Changes in the Immune Profile in Response to Treatment With Subcutaneous Abatacept in Combination With Methotrexate Versus Subcutaneous Adalimumab in Combination With Methotrexate in Adults With Early Rheumatoid Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs

NCT02557100 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT02557100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02557100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Head-to-Head, Single-Blinded Study to Assess Changes in the Immune Profile in Response to Treatment With Subcutaneous Abatacept in Combination With Methotrexate Versus Subcutaneous Adalimumab in Combination With Methotrexate in Adults With Early Rheumatoid Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 4
Overall status
Completed
Start date
November 19, 2015
Completion date
March 28, 2019
Enrollment
80 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis